Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 52: 379-382, 2006. First published January 5, 2006; 10.1373/clinchem.2005.058974
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.058974v1
52/3/379    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gadi, V. K.
Right arrow Articles by Kuhr, C. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gadi, V. K.
Right arrow Articles by Kuhr, C. S.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2006;52:379-382.)
© 2006 American Association for Clinical Chemistry, Inc.

Molecular Diagnostics and Genetics

Soluble Donor DNA Concentrations in Recipient Serum Correlate with Pancreas-Kidney Rejection

Vijayakrishna K. Gadi1,2,a, J. Lee Nelson1,2, Nicholas D. Boespflug1, Katherine A. Guthrie1,3 and Christian S. Kuhr1,4

1 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Departments of2 Medicine, 3 Biostatistics, and4 Surgery, University of Washington, Seattle, WA.

aAddress correspondence to this author at: 1100 Fairview Ave N, D2-00, Seattle, WA 98109. Fax 206-667-5255; e-mail vkgadi{at}u.washington.edu.

Background: There is no reliable serum marker available to monitor incipient pancreas or islet-cell rejection. We tested the hypothesis that quantification of donor-specific genomic DNA in serum (from tissue damage) can serve as a marker of rejection.

Methods: Using a recently developed panel of HLA-specific quantitative PCR assays (Q-PCR), we tested 158 sera from 42 pancreas-kidney transplant recipients. Temporally related biopsies for 65 sera permitted analysis for correlation of donor DNA concentrations with rejection.

Results: Donor DNA concentrations were higher in sera from recipients who had experienced allograft rejection (n = 31) than from those who had not (n = 34). Median concentrations, expressed as the genome-equivalent (gEq) number of donor cells per 106 host cells, were 2613 and 59 gEq/106, respectively (P = 0.03).

Conclusion: Q-PCR for donor-specific genetic polymorphisms merits further investigation as a noninvasive approach to monitor pancreas-kidney as well as other types of allograft rejection.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
L. A. Baxter-Lowe and M. P. Busch
Tracking microchimeric DNA in plasma to diagnose and manage organ transplant rejection.
Clin. Chem., April 1, 2006; 52(4): 559 - 561.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American Association for Clinical Chemistry.